Takashi Saito

Takashi Saito

Auto-generated profile, based on publicly available information

Takashi Saito

Department of Child Neurology National Center Hospital, National Center of Neurology and Psychiatry Tokyo Japan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
HKHirofumi Komaki
Hirofumi Komaki
TNTetsuya Nagata
Tetsuya Nagata
TSTakashi Saito
Takashi Saito
SMSatoru Masuda
Satoru Masuda
ETEri Takeshita
Eri Takeshita
STShin'ichi Takeda
Shin'ichi Takeda
Duchenne muscular dystrophy (DMD) is a lethal hereditary muscle disease caused by mutations in the gene encoding the muscle protein dystrophin. These mutations result in a shift in the open reading frame leading to loss of the dystrophin protein. Antisense oligonucleotides (ASOs) that induce exon skipping correct this frame shift during pre-mRNA splicing and partially restore dystrophin expression in mouse and dog models. We conducted a phase 1, open-label, dose-escalation clinical trial to determine the safety, pharmacokinetics, and activity of NS-065/NCNP-01, a morpholino ASO that enables skipping of exon 53. Ten patients with DMD (6 to 16 years old), carrying mutations in the dystrophin gene whose reading frame would be restored by exon 53 skipping, were administered NS-065/NCNP-01 at doses of 1.25, 5, or 20 mg/kg weekly for 12 weeks. The primary endpoint was safety; the secondary endpoints were pharmacokinetics and successful exon skipping. No severe adverse drug reactions were observed, and no treatment discontinuation occurred. Muscle biopsy samples were taken before and after treatment and compared by reverse transcription polymerase chain reaction (RT-PCR), immunofluorescence, and Western blotting to assess the amount of exon 53 skipping and dystrophin expression. NS-065/NCNP-01 induced exon 53 skipping in dystrophin-encoding mRNA in a dose-dependent manner and increased the dystrophin/spectrin ratio in 7 of 10 patients. Furthermore, the amount of exon skipping correlated with the maximum drug concentration in plasma (Cmax) and the area under the concentration-time curve in plasma (AUC0-t). These results indicate that NS-065/NCNP-01 has a favorable safety profile and promising pharmacokinetics warranting further study in a phase 2 clinical trial.

18 August 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSTakashi Saito
Takashi Saito
ANAkinori Nakamura
Akinori Nakamura
YAYoshitsugu Aoki
Yoshitsugu Aoki
Toshi YokotaToshi Yokota
Toshi Yokota
TOTakashi Okada
Takashi Okada
STShin'ichi Takeda
Shin'ichi Takeda
Antisense oligonucleotide-induced exon skipping is a promising approach for treatment of Duchenne muscular dystrophy (DMD). We have systemically administered an antisense phosphorodiamidate morpholino oligomer (PMO) targeting dystrophin exons 6 and 8 to a dog with canine X-linked muscular dystrophy in Japan (CXMDJ) lacking exon 7 and achieved recovery of dystrophin in skeletal muscle. To date, however, antisense chemical compounds used in DMD animal models have not been directly applied to a DMD patient having the same type of exon deletion. We recently identified a DMD patient with an exon 7 deletion and tried direct translation of the antisense PMO used in dog models to the DMD patient's cells. We converted fibroblasts of CXMDJ and the DMD patient to myotubes by FACS-aided MyoD transduction. Antisense PMOs targeting identical regions of dog and human dystrophin exons 6 and 8 were designed. These antisense PMOs were mixed and administered as a cocktail to either dog or human cells in vitro. In the CXMDJ and human DMD cells, we observed a similar efficacy of skipping of exons 6 and 8 and a similar extent of dystrophin protein recovery. The accompanying skipping of exon 9, which did not alter the reading frame, was different between cells of these two species. Antisense PMOs, the effectiveness of which has been demonstrated in a dog model, achieved multi-exon skipping of dystrophin gene on the FACS-aided MyoD-transduced fibroblasts from an exon 7-deleted DMD patient, suggesting the feasibility of systemic multi-exon skipping in humans.

1 February 2011 in Soil Science and Plant Nutrition
Verified
Journal Article
Open access
TSTakashi Saito
Takashi Saito
TOTakashi Otani
Takashi Otani
NSNobuyasu Seike
Nobuyasu Seike
HMHirotatsu Murano
Hirotatsu Murano
MOMasanori Okazaki
Masanori Okazaki
The use of aldrin and dieldrin as pesticides was prohibited in 1975 in Japan. However, some of the soils still remain contaminated with dieldrin, because aldrin is easily oxidized to dieldrin and dieldrin is extremely stable in soil. In recent years, dieldrin at concentrations exceeding the limit set by the Food Sanitation Law of Japan (dieldrin < 0.02 mg kg–1 fresh weight) has been detected in cucumber fruits produced in some areas of Japan. We examined the effect of the soil application of selected adsorbents on reducing dieldrin concentrations in cucumber fruits in three steps of pot experiments. Among the three types of biochar made from wood chip, rice husk, and bamboo, wood chip charcoal was found to be the most effective (pot experiment 1). The effect of wood chip charcoal was enhanced by high-temperature burning and crushing (pot experiment 2). However, the effect of activated carbon was superior to that of optimized (high-temperature-treated and crushed) wood chip charcoal (pot experiment 3). Therefore, activated carbon was selected as the most effective adsorbent. The effect of activated carbon to reduce dieldrin concentrations in cucumber fruits was confirmed in a field experiment, and the effect continued to a certain extent for at least four years after the application. We calculated the cost of activated carbon necessary to maintain a sufficient suppressive effect in the field, and this cost would appear to be acceptable to cucumber farmers. Consequently, application of activated carbon to dieldrin-contaminated soils can be considered a promising practical technique for reducing dieldrin concentrations in cucumber fruits.

23 December 2011 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
PDF file
SFShinobu Fukumura Fukumura
Shinobu Fukumura Fukumura
YSYoshiaki Saito
Yoshiaki Saito
TSTakashi Saito
Takashi Saito
HKHirofumi Komaki
Hirofumi Komaki
ENEiji Nakagawa
Eiji Nakagawa
ITItaru Takamisawa
Itaru Takamisawa
This article reports the case of a female with late infantile neuronal ceroid lipofuscinosis who developed right and left anterior bundle branch blocks and episodic bradycardia at 23 years of age. Several episodes of supraventricular tachycardia manifested at 23 and 27 years of age. In addition, a transient second‐degree atrioventricular conduction block also emerged at 27 years of age. Atrial fibrillation and aggravation of the atrioventricular conduction block resulted in progressive bradycardia and cardiac death at the age of 28 years. Cardiac involvement and accumulation of lipopigments in the myocardium and cardiac conduction system have been recognized in juvenile neuronal ceroid lipofuscinosis, but this is the first report to describe progressive conduction defects in a case of late infantile neuronal ceroid lipofuscinosis.

1 March 2016 in Brain and Development
Verified
Journal Article
Closed access
RKReiko Koichihara
Reiko Koichihara
TSTakashi Saito
Takashi Saito
AIAkihiko Ishiyama
Akihiko Ishiyama
HKHirofumi Komaki
Hirofumi Komaki
SYShota Yuasa
Shota Yuasa
MSMasayuki Sasaki
Masayuki Sasaki

18 April 2012 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
SMShinsuke Maruyama
Shinsuke Maruyama
YSYoshiaki Saito
Yoshiaki Saito
ENEiji Nakagawa
Eiji Nakagawa
TSTakashi Saito
Takashi Saito
HKHirofumi Komaki
Hirofumi Komaki
YGYu-Ichi Goto
Yu-Ichi Goto